Vantictumab
18R5-003
Phase 1 small_molecule completed
Quick answer
Vantictumab for Pancreatic Cancer is a Phase 1 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mereo BioPharma Group plc
- Indication
- Pancreatic Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed